Research ID Investigator Name Research Topic Research Status
1Panu Disease Progression of Type 2 Diabetes Mellitus: A cohort profileFor graduation
2Panu Retinopathy prediction in type 2 diabetes: time-varying Cox proportional hazards and machine learning modelsPublished
3Teerapat Treatment effectiveness of second-line drugs in prevention of HFFor graduation
4Teerapat Prognostic factors of HF in T2D MS submitted
5Sukanya Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetesPublished
6Thitiya Effect of second-line drugs on diabetic ratinopathy On going
7Thunyarat Effect of second-line drugs on fatty liver (NAFLD/NASH)On going
8Nathorn GLP1 and BMIOn going
9Montarat Cost-Utility Analysis of Laparoscopic Bariatric Surgery for Obesity with type II Diabetes MellitusFor graduation
12Thunyarat Short and Long term outcomes between patients who are treated in DM clinic vs non-DM clinicFor graduation
13AmmarinAssociation of statin therapy initiation with diabetes progression (TE+mediation)Approved
14AmmarinT2D real-world medications useDrafting MS
15Thitiya Cucurmin supplement and glycemic control On going
30Oraluck Cost-Effectiveness of Second-line Drugs for Improved Glycaemic Control for Type 2 Diabetes Mellitus in ThailandOn going
31Sukanya GLP1-RA and BW, BMI with difference in differenceDrafting MS
32Rou Tehpredictive ability of visit-to-visit glucose variability on diabetes complicationsDrafting MS
35AmmarinEffects of curcumin supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: an umbrella review and updated meta-analysisPublished
36Amarit Effects of second-line antihyperglycemic medications on chronic kidney disease progression: A multistate analysisDrafting MS
43Panu Treatment effectiveness of VEGF and laser on ocular and systemic outcomes in diabetic retinopathyOn going
44Hataikarn Effect of second-line drugs on osteoporosis and/or fracturesOn going
45Sukanya Clinical effect of SGLT2i on CKD, CVD; Mediation analysisApproved
46Sukanya Individual treatment effects of sodium-glucose cotransporter-2 inhibitors on the risk of chronic kidney disease using MLOn going
47TanawanCUA and BIA of adding SGLT2 inhibitors to standard treatment in T2D with CHFDrafting MS
48Sukanya Counterfactual prognostic model under hypothetical treatment of SGLT2i in CKD lowering risk in type 2 diabetesMS submitted
49RomenMultiple Imputation by Chained Equations using Conventional and Machine Learning Models accounting for UncertaintyOn going
52Thitiya Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trialPublished
53Panu A multistate models of T2D progression: Conventional statistical and machine learning modelsOn going
58Thunyarat Effect of second-line drugs on metabolic dysfunction-associated fatty liver disease (MAFLD)Approved
61Amarit SGLT2i and chronic kidney disease progression in T2DMS submitted
64Amarit SGLT2i effect on AKI patients: A multistate analysis from multicenter dataOn going
66Amarit Monotherapy va combined anti-diabetic drugs in T2DOn going